Restrictive versus liberal transfusion in cardiac surgery
Which transfusion threshold best balances oxygen delivery and transfusion exposure in cardiac surgery? Compare trial populations, ischemic outcomes, mortality, and the actual thresholds used—not anemia alone.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 10 of 10
Recent evidence · past year
-
Cell salvage volume and hemostatic changes in cardiac surgery: A retrospective cohort study using routine coagulation and viscoelastic assessment.
AI summary of the abstract, unverified
- Retrospective cohort of adult cardiac surgery patients using cell salvage, analyzed as a routine coagulation cohort (N = 677) and an exploratory viscoelastic cohort (N = 50).
- Exposure was cell salvage reinfusion volume, with paired hemostatic measurements before and after and no coagulation-affecting blood products between them.
- In the routine coagulation cohort, CS volume was not significantly associated with absolute changes in any parameter (all p ≥ 0.144).
- In the viscoelastic cohort, higher CS volume was associated with lower functional fibrinogen clot strength (CFF MA β = -3.31 mm/L; 95% CI -5.53 to -1.08; adjusted p = 0.031), while the CK MA association did not survive correction.
Original abstract (PubMed)
BACKGROUND: Intraoperative cell salvage (CS) reduces allogeneic transfusion in cardiac surgery, but the washing process removes coagulation factors and platelets, raising hemostatic concerns. The dose-response relationship between CS volume and perioperative hemostatic changes remains poorly characterized. METHODS: In this retrospective study of adult patients undergoing cardiac surgery with CS use, two cohorts with paired hemostatic measurements were identified: a routine coagulation cohort (primary analysis) and a viscoelastic cohort (exploratory analysis). Both cohorts were restricted to patients without coagulation-affecting blood products between measurements. Multivariable linear regression examined CS volume and absolute changes in each parameter, adjusted for surgical and patient characteristics and baseline values. RESULTS: In the routine coagulation cohort (N = 677; median CS 0.5 L, range 0.1-1.6 L), CS volume was not significantly associated with absolute changes in any parameter (all p ≥ 0.144). In the viscoelastic cohort (N = 50; median CS 0.8 L, range 0.2-3.7 L), CS volume was significantly associated with decreased functional fibrinogen clot strength (CFF MA: β = -3.31 mm/L; 95% CI: -5.53, -1.08; p = 0.004) and overall clot strength (CK MA: β = -2.93 mm/L; 95% CI: -5.73, -0.13; p = 0.041); after Holm correction for multiple testing, the CFF MA association remained significant (adjusted p = 0.031), whereas the CK MA association did not (adjusted p = 0.244). CONCLUSIONS: At observed reinfusion volumes, CS was not associated with changes in routine coagulation parameters, but in the exploratory viscoelastic cohort, higher CS volume was associated with lower functional fibrinogen clot strength. These findings highlight the potential value of viscoelastic monitoring when higher volumes are anticipated.
-
An Integrated ERAS-PBM Pathway for Cardiac Surgery: Insights and Outcomes.
AI summary of the abstract, unverified
- This single-center, retrospective before-after study compared 229 elective cardiac surgery patients on an ERAS-PBM pathway with 162 pre-ERAS patients from 2019.
- The ERAS-PBM pathway added preoperative anemia screening and treatment, adherence to restrictive transfusion thresholds, blood conservation, and care bundles run by an ERAS nurse.
- RBC transfusion fell from 38.9% to 23.6% (p = 0.0012), and the exploratory adjusted OR for transfusion was 0.59 (95% CI 0.36-0.98; p = 0.041).
- Complications fell from 66.7% to 46.3% and hospital stay shortened from 12 to 9 days, and the authors call for larger multicenter prospective studies.
Original abstract (PubMed)
Background/Objectives: Anemia is a common condition in cardiac surgery and is strongly associated with adverse outcomes, including higher transfusion requirements, increased morbidity, and prolonged hospital stay. Enhanced Recovery After Surgery (ERAS) and Patient Blood Management (PBM) are both multimodal strategies designed to improve perioperative care. This study evaluates the impact of integrating ERAS and PBM with preoperative anemia management into a single standardized pathway in elective cardiac surgery. Methods: We conducted a retrospective, single-center before-after study at Lausanne University Hospital, comparing a pre-ERAS cohort (2019) with a prospective cohort managed under the ERAS-PBM pathway (May 2023-November 2024). The ERAS-PBM pathway included systematic preoperative anemia screening and treatment, reinforcement of adherence to existing restrictive transfusion thresholds, optimized blood conservation techniques, and standardized perioperative care bundles coordinated by a dedicated ERAS nurse. The primary outcome was the rate of red blood cell (RBC) transfusions during hospitalization. Secondary outcomes included overall transfusion rates, hemoglobin levels, complications, and length of stay. Results: A total of 391 patients were included (ERAS, n = 229; pre-ERAS, n = 162). RBC transfusion rates were significantly lower in the ERAS group (23.6% vs. 38.9%, p = 0.0012), with a reduction in the number of units per patient (p = 0.0005). Hemoglobin at admission was higher in the ERAS cohort (139.5 vs. 134 g/L, p = 0.0009). Overall complication rates decreased (46.3% vs. 66.7%, p < 0.0001), including major adverse cardiovascular events and pulmonary complications. Hospital stay was shorter (9 vs. 12 days, p < 0.0001), as was mechanical ventilation time (0 vs. 2.1 h, p < 0.0001). Anemic patients at admission were more transfused (39.3% vs. 18.6%, p = 0.002). Within the ERAS group, RBC transfusion was associated with higher rates of selected postoperative complications and longer ICU and hospital stays. In an exploratory multivariable logistic regression analysis, ERAS-PBM implementation was associated with lower odds of RBC transfusion during hospitalization (adjusted OR 0.59, 95% CI 0.36-0.98; p = 0.041). Conclusions: The integration of ERAS and PBM into a single multimodal pathway was associated with significant reductions in transfusion rates, complications, and length of stay in elective cardiac surgery. Anemia at admission and perioperative transfusion were associated with worse outcomes, emphasizing the importance of anemia management. Larger, multicenter prospective studies are warranted to confirm these results and to optimize anemia correction strategies, including earlier treatment of iron deficiency and outpatient erythropoietin use.
-
Perioperative hemostatic therapy in adult cardiac surgery: a narrative review highlighting human factors.
AI summary of the abstract, unverified
- This narrative review synthesizes fourteen original studies covering nearly 220,000 patients from over 1,000 centres worldwide.
- It focuses on platelet concentrate and fresh frozen plasma use in adult cardiac surgery and how hemostatic therapy varies between centres.
- Platelet and plasma transfusion rates differed significantly across centres, and patient and procedural characteristics do not fully explain these differences.
- Viscoelastic tests have improved assessment in some settings but have not eliminated variation, which the authors attribute partly to hospital culture, organization, thresholds and human factors.
Original abstract (PubMed)
Severe bleeding remains a significant cause of morbidity and mortality in cardiac surgery, and hemostatic blood components, mainly platelet concentrates and fresh frozen plasma, are essential to perioperative hemostatic management. While restrictive strategies for packed red blood cell transfusions are now well established within Patient Blood Management, inappropriate prophylactic transfusions of these hemostatic therapies continue to receive less attention.This narrative review investigates variations in hemostatic therapy among centres for adult cardiac surgery, and examines the factors that might explain these differences. A review of fourteen original studies involving nearly 220,000 patients from over 1,000 centres worldwide revealed significant variations in platelet and fresh-frozen plasma transfusion rates across centres.Differences in patient and procedural characteristics cannot entirely explain these variations. Although viscoelastic hemostatic tests have improved bedside assessment and lowered exposure in some settings, they have not eradicated significant variations in practice. The available evidence indicates that hospital culture, local organization, transfusion thresholds, and human factors all have an impact on transfusion behaviour.Optimizing the use of hemostatic therapies in adult cardiac surgery will therefore not only require better tools and protocols, but also increased focus on the organizational and non-technical factors that influence decision-making.
-
RESULT-Hip. The impact of restrictive compared with liberal transfusion strategy on cardiac injury and death in patients undergoing surgery for hip fracture : protocol for a multicentre, randomized controlled trial of two blood transfusion strategies.
AI summary of the abstract, unverified
- Protocol for a multicentre randomized controlled trial in patients aged 60 or older with anaemia (haemoglobin ≤90 g/l) undergoing surgery for hip fracture.
- Compares a liberal transfusion strategy (haemoglobin target 90 to 110 g/l) with a restrictive strategy (target 75 to 90 g/l) from randomization to discharge or 30 days.
- No efficacy results are reported; the primary outcome is a composite of death or major adverse cardiac events, adjudicated by blinded experts, with quality of life assessed at 120 days.
- The authors reduced the target sample size from 1,984 to 842 and added myocardial injury after non-cardiac surgery (MINS) to the primary outcome after recruitment fell short.
Original abstract (PubMed)
AIMS: Hip fracture is a global health issue. Complications are common, leading to reduced quality of life or death. These occur more frequently if anaemia is present. We hypothesize that correcting anaemia in the perioperative period may decrease major adverse cardiac events (MACE) and death after hip fracture. METHODS: This multicentre prospective randomized trial compares transfusion strategies after hip fracture in patients aged ≥ 60 years. We initially planned to randomize 1,984 participants with anaemia, defined as haemoglobin ≤ 90 g l-1, to one of two transfusion strategies: liberal transfusion (aim haemoglobin 90 g l-1 to 110 g l-1), or restrictive transfusion (aim 75 g l-1 to 90 g l-1). The intervention lasts from randomization to hospital discharge or 30 days post randomization, whichever is soonest. The primary outcome measure was a composite of death or MACE adjudicated by blinded clinical experts. Secondary outcomes included all-cause mortality and quality of life, evaluated at 120 days. Cost-effectiveness and health economic evaluation will also be reported. RESULTS: This trial was funded by the National Institute for Health and Care Research, HTA award (National Institute for Health and Care Research (NIHR) 130875) and registered at ISRCTN 28818784. Ethical approval was obtained to recruit patients in the UK. As recruitment fell short of the initial target, and following consultation with the funder, we refined our primary outcome to include myocardial injury after non-cardiac surgery (MINS), and reduced the required sample size to 842. CONCLUSION: Recruitment commenced on 10 June 2022. The first participant was recruited on 16 June 2022. We will engage clinicians and healthcare planners to implement the findings. We plan to recruit until 31 October 2026. Results will be disseminated to clinicians, policymakers, patients, and the public.
-
From liberal to restrictive and beyond: a narrative review of red blood cell transfusion strategies in the modern era.
AI summary of the abstract, unverified
- This narrative review of red blood cell transfusion thresholds draws on 2021–2026 trials, meta-analyses, and guidelines identified through PubMed and Google Scholar searches.
- It compares restrictive (Hb 7–8 g/dL) and liberal (Hb above 10 g/dL) strategies, then considers population-specific exceptions and ultra-restrictive thresholds (Hb <6–7 g/dL).
- The 2025 Cochrane update (48 trials, >20,000 participants) reported that restrictive strategies reduced the proportion receiving at least one transfusion by 41%, without increasing 30-day mortality or major morbidity.
- Restrictive thresholds appear safe in stable critically ill patients, non-cardiac surgery, and acute GI bleeding, while acute MI, neurocritical care, thalassemia, and hematologic malignancies need individualized approaches.
Original abstract (PubMed)
BACKGROUND: Red blood cell (RBC) transfusion remains a cornerstone of modern medicine, yet optimal transfusion thresholds continue to be debated. Historically, liberal strategies -maintaining hemoglobin (Hb) concentration above 10 g/dL- predominated, but evidence from the 1990s onward has favored restrictive approaches (Hb threshold 7-8 g/dL). This narrative review synthesizes contemporary evidence on restrictive versus liberal transfusion strategies published between 2021 and 2026, evaluates population-specific considerations, and explores emerging ultra-restrictive thresholds. MATERIALS AND METHODS: A structured narrative literature search was conducted in PubMed and Google Scholar with particular emphasis on evidence published between 2021 and 2026. Evidence from randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines is critically discussed. RESULTS: The 2025 Cochrane update (48 trials, >20,000 participants) provided high-certainty evidence that restrictive strategies induce a reduction in the risk or proportion of patients receiving at least one RBC transfusion by 41% without increasing 30-day mortality or major morbidity. Restrictive thresholds are safe in stable critically ill patients, in those undergoing non-cardiac surgery, and in patients with acute gastrointestinal bleeding. However, important exceptions include: acute myocardial infarction (in which liberal strategies may reduce cardiac events), neurocritical care (conflicting evidence on neurological outcomes), chronic transfusion-dependent conditions such as thalassemia (liberal strategies are disease-modifying), and hematologic malignancies (individualized approach required). Ultra-restrictive thresholds (Hb <6-7 g/dL) have emerged as a potential blood conservation tool during shortages but require further safety validation. DISCUSSION: Restrictive transfusion strategies are safe and effective for many stable adult hospitalized patients, reducing blood product utilization without compromising outcomes. However, individualized approaches remain essential for specific high-risk populations. Ultra-restrictive strategies are promising, but these approaches should currently be considered only in selected contexts pending further safety validation.
-
The TIMELESS Project: A Mixed-Methods Analysis of Modifiable Risk Factors and Transfusion Practices in 24,000 Cardiac Surgical Cases.
AI summary of the abstract, unverified
- A mixed-methods quality initiative at one high-volume cardiac surgery center combined a retrospective review of 24,005 adult patients (2018–2024) with a survey of 112 of 258 providers.
- The retrospective analysis examined modifiable risk factors, including preoperative anemia, malnutrition, hypothermia, hyperglycemia, and antifibrinolytic use, and their association with transfusion.
- Transfusion occurred in 55.9% of patients; preoperative anemia (IRR 1.74, 95% CI 1.67-1.83) and hypothermia (IRR 1.66, 95% CI 1.59-1.73) were linked to higher risk-adjusted transfusion, while antifibrinolytics were linked to less (IRR 0.90, 95% CI 0.86-0.93).
- Many transfusions were given without laboratory guidance (RBC 32.1%, plasma 82.4%), and 81% of responding providers endorsed a restrictive hemoglobin threshold of under 7.5 g/dL for stable patients.
Original abstract (PubMed)
BACKGROUND: Approximately 10% to 15% of all red blood cell (RBC) transfusions in the United States and United Kingdom occur during cardiac surgery. Despite efforts to standardize patient blood management, transfusion practices remain highly variable across providers and institutions. We launched the Transfusion Improvement to Minimizing Excess in Cardiac Surgery (TIMELESS) initiative to identify modifiable drivers of transfusion at our high-volume cardiac surgery center. METHODS: Our mixed-methods approach combined a retrospective data review and a survey to assess perioperative RBC and blood component (platelets, plasma, cryoprecipitate) transfusion through three key domains: (1) preoperative assessment/optimization (evaluation of modifiable risk factors for transfusion: preoperative anemia, malnutrition, anticoagulant/platelet inhibitor use); (2) perioperative blood conservation (modifiable risk factors: intraoperative antifibrinolytic use, hyperglycemia, perioperative hypothermia); (3) transfusion behaviors (laboratory guidance and transfusion triggers). These domains were investigated through (i) a retrospective database analysis that examined the association of risk factors with total intraoperative and early postoperative blood product transfusion in adult cardiac surgical patients between January 2018 and June 2024; and (ii) a structured front-line provider survey that examined opinions and behaviors that drive blood transfusion (including transfusion thresholds, triggers, and barriers to laboratory-guided practice) in anesthesia, surgical, and intensive care unit caregivers. RESULTS: Of 24,005 cardiac surgical patients in the database review, 13,420 (55.9%) received transfusions during surgery and/or early postoperatively. Of 258 front-line providers surveyed, 112 (43%) responded. Preoperative assessment/optimization (domain #1) and perioperative blood conservation (#2) found that five of six modifiable factors were associated with greater risk-adjusted transfusion: preoperative anemia (incidence rate ratio [IRR] 1.74, 95% confidence interval [CI], 1.67-1.83), malnutrition (IRR 1.44, 95% CI, 1.36-1.54), perioperative hypothermia (IRR 1.66, 95% CI, 1.59-1.73), and hyperglycemia (IRR 1.02 per 10 mg/dL, 95% CI, 1.02-1.02), whereas antifibrinolytic therapy was associated with reduced transfusion (IRR 0.90, 95% CI, 0.86-0.93). Transfusion triggers/laboratory guidance (#3) found that many transfusions were given empirically without laboratory-guidance (RBC 32.1%, platelets 44.9%, cryoprecipitate 55.0%, plasma 82.4%). Survey found that most providers (91/112, 81%) endorsed restrictive hemoglobin thresholds (<7.5 g/dL) for stable, non-bleeding patients; platelet and cryoprecipitate transfusion thresholds varied by specialty; laboratory-guidance was omitted for urgent bleeding/coagulopathy (99/112, 88%), prolonged surgical time (49/112, 44%), and long laboratory turnaround time (49/112, 44%). CONCLUSIONS: This large mixed-methods quality initiative identified modifiable risk factors, provider opinions, and transfusion behaviors to understand key drivers of transfusion in our cardiac surgery center. These results lay the groundwork to modify risk factors and transfusion behaviors and ultimately optimize perioperative blood transfusion therapy.
-
Postoperative anaemia and long-term survival following cardiac surgery: a multicentre, retrospective, observational study.
AI summary of the abstract, unverified
- Retrospective multicentre cohort of 25,697 adult cardiac surgery patients from two Danish tertiary centres, covering 2000 to 2024.
- Anaemia at hospital discharge was classified by WHO sex-specific criteria as mild or moderate-severe, and 93.1% of patients were anaemic.
- Moderate-severe anaemia was independently associated with worse survival (adjusted HR 1.11, 95% CI 1.01-1.21, p = 0.034), while discharge haemoglobin added little prognostic information beyond baseline factors.
- Haemoglobin plateaued about 4 months after discharge but stayed below baseline at 1 year, and the authors describe the postoperative anaemia association as weak and support further trials.
Original abstract (PubMed)
INTRODUCTION: Pre-operative anaemia is associated with adverse outcomes following cardiac surgery. However, the prognostic impact of postoperative anaemia is characterised incompletely. We examined whether anaemia at hospital discharge independently predicts long-term survival and characterised haemoglobin recovery trajectories during the first postoperative year. METHODS: This retrospective multicentre cohort study included 25,697 adult cardiac surgery patients from two Danish tertiary centres (2000-2024). Anaemia was classified using World Health Organization sex-specific criteria as mild (haemoglobin 110-129 g.l-1 for men; 110-119 g.l-1 for women) or moderate-severe (haemoglobin < 110 g.l-1 for both). The primary outcome was overall survival from surgery to death or censoring at end of follow-up. Cox proportional hazards regression assessed associations between anaemia at discharge and mortality, adjusting for age, sex, pre-operative haemoglobin and comorbidities. Restricted cubic splines examined non-linear relationships between haemoglobin and mortality. RESULTS: At discharge, 23,935 (93.1%) patients were anaemic (8384 (32.6%) mild anaemia and 15,551 (60.5%) moderate-severe anaemia). Moderate-severe anaemia was independently associated with worse survival (hazard ratio 1.11, 95%CI 1.01-1.21, p = 0.034) in adjusted analysis. Cubic spline analysis revealed a steep, non-linear relationship between pre-operative haemoglobin and mortality, whereas discharge haemoglobin provided limited prognostic information beyond baseline characteristics and surgical complexity. Haemoglobin recovery plateaued around 4 months after discharge, but the average haemoglobin level remained below baseline even after 1 year. DISCUSSION: Postoperative anaemia showed a weak independent association with long-term mortality, in contrast to the clear dose-response relationship observed for pre-operative anaemia. The near-universal prevalence of postoperative anaemia and incomplete haemoglobin recovery at 1 year support further trials of peri-operative anaemia management.
PubMed 42478340 Publisher (DOI) PubMed types: Journal Article, Multicenter Study, Observational Study -
Perioperative Transfusion Trigger Score Versus Restrictive Transfusion in Older Non-Cardiac Surgery Patients: A Multicenter Randomized Controlled Trial.
AI summary of the abstract, unverified
- Multicenter randomized trial at two Chinese hospitals enrolled 253 patients aged 60 or older undergoing non-cardiac surgery, randomized 1:1.
- Patients were assigned to POTTS-guided transfusion, a score built from adrenaline use, FiO2, temperature and angina history, or to control care following the 2012 AABB guideline.
- Transfusion was required in 24.00% (30/125) of POTTS patients versus 35.94% (46/128) of controls (p = 0.038), with no significant difference in transfusion volume.
- The authors concluded POTTS reduced the proportion transfused without increasing complications, though complication rates were 12.80% versus 8.59% (p = 0.279), not significantly different.
Original abstract (PubMed)
BACKGROUND: Restrictive transfusion (Hb < 7 g/dL) is recommended for most perioperative patients, but the optimal threshold for those with cardiovascular disease or Hb 7-10 g/dL remains uncertain. The Perioperative Transfusion Trigger Score (POTTS), which integrates adrenaline requirement, FiO2, temperature, and angina history, may standardize decisions and safely reduce transfusions in older non-cardiac surgery patients. METHODS: This multicenter RCT in two Chinese hospitals randomized patients ≥ 60 years undergoing non-cardiac surgery 1:1 to POTTS or control. POTTS = 6 plus points for adrenaline, FiO2 (to maintain SpO2 ≥ 95%), core temperature, and angina; transfusion when Hb < POTTS. Control followed 2012 AABB guideline (Hb < 7 always transfuse; > 10 not; 7-10 physician discretion). PRIMARY OUTCOME: proportion receiving allogeneic RBC transfusion during perioperative period (ITT population). RESULTS: 253 patients (mean age 72.3 years; 67.6% women) were randomized (May 2023-Sept 2025). Baseline Hb similar (median 9.60 vs. 9.50 g/dL). In ITT, transfusion required in 24.00% (30/125) of POTTS vs. 35.94% (46/128) of control (p = 0.038). Transfusion volume did not differ significantly (median 2.50 vs. 3.00 units, p = 0.520). Overall complication rates: 12.80% vs. 8.59% (p = 0.279); one death in control group (0.85%). No significant differences in specific complications. CONCLUSION: In patients ≥ 60 years undergoing non-cardiac surgery, POTTS-guided transfusion significantly reduced the proportion of patients transfused without increasing complications. TRIAL REGISTRATION: This study was registered at http://www.chictr.org.cn (#ChiCTR2300071739).
PubMed 42378627 Publisher (DOI) PubMed types: Journal Article, Multicenter Study, Randomized Controlled Trial -
Coagulopathy in Cardiac Surgery: A Scoping Review of Prothrombin Complex Concentrate.
AI summary of the abstract, unverified
- This scoping review (PRISMA-ScR) mapped 57 primary studies and 15 reviews on 4-factor PCC in adults undergoing on-pump cardiac surgery.
- The comparator was FFP, and reported PCC dosing ranged from fixed 500-4000 IU to weight-based 15-30 IU/kg.
- Evidence consistently suggests PCC reduces chest tube output and transfusion versus FFP, though effect sizes vary; no pooled estimates are reported.
- The authors conclude that gaps remain on optimal dose, timing, viscoelastic targets, and fibrinogen sequencing, with limited cost-effectiveness data and rare serious adverse events.
Original abstract (PubMed)
BACKGROUND: Coagulopathy after cardiopulmonary bypass substantially contributes to postoperative bleeding, transfusion requirements, morbidity, and mortality. The traditional treatment option is fresh frozen plasma (FFP), but prothrombin complex concentrate (PCC) has become an alternative in the past years. AIM: This study aimed to systematically map the current evidence and identify critical knowledge gaps regarding the efficacy, optimal timing, dosing regimens, point-of-care testing guidance, administration order, cost-effectiveness, and safety of 4-factor PCC in adult patients undergoing on-pump cardiac surgery, thereby informing future research priorities. METHOD: A scoping review was conducted following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. A search of several databases was conducted on 8 April 2025 without restrictions on the language or date of the publications. Study selection, data extraction, and charting were performed independently by two mutually blinded reviewers. RESULTS: A total of 57 primary studies (seven randomised controlled trials, 36 retrospective cohorts, five prospective cohorts, and nine experimental investigations) and 15 reviews with or without meta-analyses were identified. Evidence consistently indicates that PCC reduces postoperative chest tube output and transfusion requirements compared with FFP, although the effect sizes vary. Reported dosing ranged from fixed 500-4000 IU to weight-based 15-30 IU kg-1. Viscoelastic testing guides PCC administration; however, standardised thresholds are lacking. Limited data suggest that PCC may be more cost-effective than FFP, and serious adverse events appear to be rare. No study has directly compared different PCC dosing regimens or prophylactic use in high-risk patients. CONCLUSIONS: Substantial evidence gaps remain concerning the optimal dose, timing, viscoelastic targets, sequencing with fibrinogen concentrate, and health economic analyses of PCC use in cardiac surgery. High-quality randomised trials addressing these unanswered questions are warranted to refine the clinical guidelines.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
-
Red blood cell transfusion practices in two surgical intensive care units: a mixed methods assessment of barriers to evidence-based practice.
AI summary of the abstract, unverified
- Mixed-methods study in two Baltimore ICUs (cardiac surgical and surgical), combining 52 observed patient encounters, provider surveys, and chart review.
- No intervention was tested; the authors compared prescribers with bedside nurses on their views of the ideal pretransfusion hemoglobin and on actual practice.
- Prescribers in both units (87% and 90%) more often than nurses (8% and 42%) named 7 g/dL or lower as ideal for nonbleeding patients (p = 0.002 and 0.015).
- The authors concluded that knowledge gaps, overly optimistic views of current practice, and variable thresholds between prescribers are barriers, and that targeted interventions are needed.
Original abstract (PubMed)
BACKGROUND: Despite evidence supporting restrictive red blood cell (RBC) transfusion thresholds and the associated clinical practice guidelines, clinical practice has been slow to change in the intensive care unit (ICU). Our aim was to identify barriers to conservative transfusion practice adherence. STUDY DESIGN AND METHODS: A mixed-methods study involving observation of prescriber (i.e., physicians, physician assistants, nurse practitioners) and bedside nurse daily bedside rounds, provider survey, and medical record abstraction was conducted in one cardiac surgical ICU (CSICU) and one surgical ICU (SICU) in an academic hospital in Baltimore, Maryland. RESULTS: Of 52 patient encounters observed during bedside rounds, 38 (73%) involved patients without evidence of active bleeding or cardiac ischemia. Surveys were completed by 52 (93%) of the 56 providers participating in rounds. Prescribers in the CSICU and SICU (87 and 90%, respectively) indicated the ideal pretransfusion hemoglobin (Hb) to be not more than 7 g/dL in nonbleeding and/or nonischemic patients compared to a minority of nurses (8% [p = 0.002] and 42% [p = 0.015], respectively). Prescribers and nurses in both ICUs overestimated the typical pretransfusion Hb in their units (CSICU, p < 0.001; SICU, p = 0.019). During rounds, providers infrequently explicitly discussed Hb monitoring or transfusion thresholds (33%) despite most (60%) reporting significant variation in transfusion thresholds between individual prescribers. CONCLUSIONS: Our study identified several provider and system barriers to evidence-based transfusion practices including knowledge differences, overly optimistic estimates of current practice, and heterogeneous transfusion practice in each ICU. Further work is necessary to develop targeted interventions to improve evidence-based RBC transfusion practices.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.